Abstract:The Wnt/β-catenin signaling pathway plays extensive roles in cancer initiation, proliferation, and development, and has been implicated in the regulation of stem cells in the intestinal crypt, widely accepted as responsible for colorectal cancer (CRC) origination. This pathway has been a target of interest for many years for chemotherapeutic development of CRC due to its implication in most cases. Previously, a series of naphthoquinone analogs have been identified to inhibit the Wnt/β-catenin. It was postulated that these compounds exhibit their inhibitory activity via binding to β-catenin at the β-catenin/TCF4 interaction interface. In this study, we aimed to further define the critical pharmacophore for these compounds and verify their mechanisms of action for their abilities to inhibit the Wnt/β-catenin signaling pathway. Interestingly, our data suggested two of the compounds, compounds 3 and 6, may potently inhibit the Wnt/β-catenin signaling pathway via inhibition of the TCF4/DNA interaction, a novel finding compared to previous studies on these compounds. Our computational studies suggested that the compounds bound within the DNA binding HMG-box domain of TCF4 to elicit their inhibitory action. These compounds inhibited Wnt signaling in a dose dependent manner, suppressed Wnt direct target genes and demonstrated unforeseen degradation of the TCF4 protein. Thus, this study revealed a potentially novel mechanism of action of the chloro-naphthoquinone as possibly a multi-targeting scaffold, which warrants further investigation in future drug discovery on the 'undruggable" TCF proteins and an aberrantly activated Wnt/β-catenin signaling pathway.

Development of a Novel Fluorescence Polarization–Based Assay for Studying the Β-Catenin/tcf4 Interaction

Development of Structure-Based Pharmacophore to Target the Β-Catenin-tcf Protein–protein Interaction

Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.

Molecular docking-aided identification of small molecule inhibitors targeting β-catenin-TCF4 interaction

Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners

Exploration of naphthoquinone analogs in targeting the TCF-DNA interaction to inhibit the Wnt/β-catenin signaling pathway

A Tumor-Targeting and Polarity-Specific Near-Infrared Fluorescent Probe for Accurate Cancer Diagnosis in Vivo

A New Assay Based on Fluorescence Resonance Energy Transfer to Determine the Binding Affinity of Bcl-xLInhibitors

Design, synthesis, and biological evaluation of new diaminoquinazolines as β-catenin/Tcf4 pathway inhibitors.

Targeting the β-catenin signaling for cancer therapy

Lysosome-Targeting Fluorogenic Probe For Cathepsin B Imaging In Living Cells

Fluorescence polarization for the evaluation of small-molecule inhibitors of PCAF BRD/Tat-AcK50 association.

Development of a Microscopy-Based Assay for Protein Kinase Cζ Activation in Human Breast Cancer Cells

Pharmacological Inhibition of Β-Catenin/bcl9 Interaction Overcomes Resistance to Immune Checkpoint Blockades by Modulating T Reg Cells

Identification and biological evaluation of fused tetrahydroisoquinoline derivatives as Wnt/β-catenin signaling inhibitors to suppress colorectal cancer

Dual‐Mechanism Quenched Fluorogenic Probe Provides Selective and Rapid Detection of Cathepsin L Activity**

C644‐0303, a small‐molecule inhibitor of the Wnt/β‐catenin pathway, suppresses colorectal cancer growth

Design, Synthesis and Biological Evaluation of Quercetin Derivatives As Novel Β-Catenin/b-cell Lymphoma 9 Protein−protein Interaction Inhibitors

In Vivo And In Vitro Models For The Therapeutic Targeting Of Wnt Signaling Using A Tet-O Delta N89 Beta-Catenin System

Targeting Wnt/β-Catenin Pathway for Drug Therapy

Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors